The French industrial group specializing in the formulation, manufacturing and packaging of products for the healthcare, beauty and food supplement sectors, is launching a new platform dedicated to supporting individuals on GLP-1 treatments.
At CPHI Milan, taking place from 6 to 8 October 2026, Anjac Health & Beauty is unveiling a range of solutions designed to address the key needs associated with these treatments and support patients throughout their care journey.
Used for around two decades in the treatment of type 2 diabetes, analogues of these hormones are now also indicated for obesity management and weight control, and their use is increasing worldwide.
According to Anjac Health & Beauty, the new use of GLP-1 treatments is opening up an area of innovation at the intersection of medicine, nutrition and dermocosmetics, addressing needs such as digestive comfort, hydration, micronutrient balance, preservation of muscle mass, and skin and hair care.
Anjac aims to position itself at the intersection of these evolving needs, enabling pharmaceutical companies, consumer healthcare players, and beauty and wellness brands to address these emerging needs and strengthen their offering.
The French group is able to offer a multi-category portfolio spanning medicines, medical devices, food supplements and cosmetic products, supported by its proprietary technologies and its formulation and regulatory expertise, tailored to the requirements of major international markets.
Available in a wide range of forms and formats, the product portfolio developed by Anjac Health & Beauty is designed to integrate into patients’ daily routines and address the main areas of discomfort experienced throughout treatment, from initiation through long-term maintenance. It also includes dedicated post-treatment solutions, supporting a return to a balanced diet, preservation of muscle mass, and skin and hair care. The offering is available as a turnkey solution, as a complete portfolio or on an à la carte basis, and can also be developed on a bespoke basis.
"The rapid development of GLP-1 treatments is creating new needs that go beyond taking the medication itself. Patients need to be able to stay the course over time, and this is often where the success of treatment is determined. Our ambition is to support them at every stage of their journey, from medical initiation through to post-treatment, helping to preserve the benefits over the long term. This also reflects what innovation means at Anjac: anticipating changes in needs and behaviours and bringing together our expertise in healthcare, nutrition and beauty to provide our clients with concrete solutions in a segment that is still taking shape," says Emmanuelle Raillard-Labbe, Chief Strategic Growth Officer, Anjac Health & Beauty.
